FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 462 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ November 29, 2021 Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... November 20, 2019 Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials June 29, 2020 Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... August 25, 2025 Load more HOT NEWS FDA Approves New Interchangeable Biosimilar to Pertuzumab Lessons from the green: How sports psychology helped a top golf... New drug combo for advanced breast cancer approved for NHS in... FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer
